U.S. markets closed

Medical Marijuana, Inc. (MJNA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0143+0.0001 (+1.06%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0141
Open0.0144
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0140 - 0.0170
52 Week Range0.0100 - 0.0600
Volume7,861,793
Avg. Volume16,248,333
Market Cap57.089M
Beta (5Y Monthly)-0.12
PE Ratio (TTM)N/A
EPS (TTM)-0.0040
Earnings DateApr 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Supports European Industrial Hemp Association in Opinion Letter on Legal Status of CBD and Hemp

    SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® is proud to support the European Industrial Hemp Association (EIHA) in its recent opinion letter to the European Commission on the legal status of cannabidiol (CBD) and hemp.  EIHA’s letter was written in response to the European Commission’s decision to suspend all applications for hemp extracts and natural cannabinoids under the European Union’s Novel Food rules and also deem under a “preliminary conclusion” that extracts from the flowering and fruiting tops of the hemp plant should be considered a drug under the United Nations Single Convention on Narcotic Drugs of 1961. EIHA explains that the decision is “not based on the latest scientific literature nor inspired by the current debate at the United Nations level.”EIHA believes that industrial hemp and its downstream products are not narcotic or psychotropic drugs. Hemp is exempted from the scope of the United Nations Single Convention of 1961, which features a clear distinction between cannabis varieties grown for the production of drugs and exempting cannabis grown for any other purpose (with low levels of THC). “Hemp has been a food source for centuries and for decades the EU has stated that hemp extracts are not novel. It seems like a political move to now attempt to change its legal status,” said Kannaway® Managing Director of International Janne Heimonen. “There is great consumer demand for products and hemp farming supports the EU’s ambitious sustainability goals. We are fully committed to helping the industry keep providing consumers the products they need.”Kannaway® has led the CBD industry in Europe since 2018. In December 2019, Kannaway® executives spoke in the European Parliament at a special event on "The State of Hemp in Europe” about how to improve the European hemp market for all of its applications including CBD products. “Kannaway has pioneered the hemp CBD industry in Europe and plans to continue to grow its robust market there,” said Kannaway® CEO Blake Schroeder. “Our portfolio of Companies has worked with government leaders around the world to make sure that people have legal access to CBD and we will do the same in Europe.”To learn more about Kannaway®, please visit http://www.kannaway.com. About KannawayKannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here.Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.CONTACT: Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 858-264-6600 andrew.hard@cmwmedia.com www.cmwmedia.comInvestor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.com

  • Medical Marijuana, Inc. Subsidiary Kannaway® Welcomes Distinguished Sales and Marketing Expert Carolyn Dielmann Connolly as Brand Ambassador
    GlobeNewswire

    Medical Marijuana, Inc. Subsidiary Kannaway® Welcomes Distinguished Sales and Marketing Expert Carolyn Dielmann Connolly as Brand Ambassador

    MJNA Carolyn Dielmann Connolly, Kannaway® Brand AmbassadorSAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® welcomes Carolyn Dielmann Connolly to the Company’s team of brand ambassadors."Having seen all that Carolyn has accomplished in her previous roles, I am humbled and excited to have her join Kannaway," said Kannaway® CEO Blake Schroeder. "We look forward to working alongside her as she develops her global leadership team at Kannaway and helps us continue to reach new customers.”Connolly has spent her networking career with a few well-known companies and has built a reputation as a top money earner. In that role, she also became a National Certified Trainer, Core Market Leader and Travel Committee Board Member. She has built, trained and led successful teams across the health and wellness sector of the network marketing industry and developed leaders, systems and step-by-step programs to help others be successful. Previously, she expanded her direct selling skills while working with NuSkin International and serving in various sales and marketing positions throughout her career. "I have studied the CBD industry closely over the past few years and wanted to get involved because of the immense potential it has both in its ability to help many consumers and as a financial opportunity," said Connolly. "I am confident in my ability to build a strong and passion-driven team around Kannaway’s strong values and innovative offerings.”About KannawayKannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here.Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.FORWARD-LOOKING DISCLAIMER This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.LEGAL DISCLOSURE Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.CONTACT: Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 858-264-6600 andrew.hard@cmwmedia.com www.cmwmedia.comInvestor Relations Contact: P. (858) 283-4016 Investors@medicalmarijuanainc.comAttachment * MJNA

  • GlobeNewswire

    Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Unveils World’s First COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization

    SAN DIEGO, July 21, 2020 -- via NEWMEDIAWIRE -- Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that.